Melpomeni Fani

5.2k total citations
92 papers, 3.8k citations indexed

About

Melpomeni Fani is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Melpomeni Fani has authored 92 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 56 papers in Radiology, Nuclear Medicine and Imaging and 55 papers in Epidemiology. Recurrent topics in Melpomeni Fani's work include Neuroendocrine Tumor Research Advances (55 papers), Radiopharmaceutical Chemistry and Applications (53 papers) and Lung Cancer Research Studies (32 papers). Melpomeni Fani is often cited by papers focused on Neuroendocrine Tumor Research Advances (55 papers), Radiopharmaceutical Chemistry and Applications (53 papers) and Lung Cancer Research Studies (32 papers). Melpomeni Fani collaborates with scholars based in Switzerland, Germany and United States. Melpomeni Fani's co-authors include Helmut R. Maëcke, Damian Wild, Guillaume Nicolas, Jean Claude Reubi, Wolfgang Weber, Rosalba Mansi, Subhani M. Okarvi, João Paulo André, Renzo Cescato and Emanuel Christ and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Melpomeni Fani

86 papers receiving 3.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melpomeni Fani Switzerland	34	2.1k	2.1k	1.8k	812	543	92	3.8k
Elisabeth von Guggenberg Austria	29	1.5k 0.7×	1.5k 0.7×	1.4k 0.8×	718 0.9×	388 0.7×	76	3.0k
Marco Chinol Italy	32	1.7k 0.8×	1.5k 0.7×	1.5k 0.8×	995 1.2×	354 0.7×	95	3.5k
Mattias Sandström Sweden	38	3.1k 1.4×	1.9k 0.9×	1.0k 0.6×	562 0.7×	806 1.5×	86	4.1k
Jack L. Erion United States	26	1.3k 0.6×	1.3k 0.6×	1.4k 0.8×	687 0.8×	415 0.8×	42	2.6k
Wout A. P. Breeman Netherlands	40	2.6k 1.2×	3.3k 1.6×	4.1k 2.3×	2.3k 2.9×	623 1.1×	84	6.2k
Irina Velikyan Sweden	25	1.5k 0.7×	990 0.5×	681 0.4×	276 0.3×	394 0.7×	78	2.5k
Stanislas Pauwels Belgium	29	1.3k 0.6×	1.8k 0.8×	2.1k 1.1×	1.2k 1.5×	341 0.6×	76	3.5k
Margret Schottelius Germany	44	3.8k 1.8×	2.4k 1.2×	663 0.4×	278 0.3×	1.1k 2.0×	114	6.1k
A. Heppeler Switzerland	11	1.2k 0.6×	1.3k 0.6×	1.6k 0.9×	897 1.1×	188 0.3×	13	2.4k
Marleen Melis Netherlands	27	964 0.5×	904 0.4×	750 0.4×	272 0.3×	451 0.8×	42	2.3k

Countries citing papers authored by Melpomeni Fani

Since Specialization

Citations

This map shows the geographic impact of Melpomeni Fani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melpomeni Fani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melpomeni Fani more than expected).

Fields of papers citing papers by Melpomeni Fani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melpomeni Fani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melpomeni Fani. The network helps show where Melpomeni Fani may publish in the future.

Co-authorship network of co-authors of Melpomeni Fani

This figure shows the co-authorship network connecting the top 25 collaborators of Melpomeni Fani. A scholar is included among the top collaborators of Melpomeni Fani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melpomeni Fani. Melpomeni Fani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaonkar, Raghuvir H., Thèodorine Bailly, Jacopo Millul, et al.. (2025). Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4. ChemMedChem. 20(6). e202400773–e202400773. 1 indexed citations

Ulaner, Gary A., et al.. (2025). ⁶¹ Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of ⁶¹ Cu-labeled PET Radiotracers. Radiology. 317(3). e251151–e251151.

Nicolas, Guillaume, Lisa McDougall, Felix Kaul, et al.. (2025). First-in-human administration of [61Cu]Cu-NODAGA-LM3 and head-to-head comparison with [68Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study. European Journal of Nuclear Medicine and Molecular Imaging. 53(2). 710–712.

McDougall, Lisa, Andreas Bauman, Peter Bernhardt, et al.. (2024). Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study. Journal of Nuclear Medicine. 65(4). 573–579. 8 indexed citations

Mansi, Rosalba, Luigi Del Pozzo, Raghuvir H. Gaonkar, et al.. (2024). ⁶¹Cu-PSMA–Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging. Journal of Nuclear Medicine. 65(9). 1427–1434. 8 indexed citations

Mansi, Rosalba, Raghuvir H. Gaonkar, Melpomeni Fani, et al.. (2023). CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors. Journal of Translational Medicine. 21(1). 604–604. 3 indexed citations

Millul, Jacopo, et al.. (2023). Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. European Journal of Nuclear Medicine and Molecular Imaging. 50(10). 3050–3061. 48 indexed citations

Janota, Barbara, Alicja Hubalewska‐Dydejczyk, Melpomeni Fani, et al.. (2023). Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study. Pharmaceutics. 15(3). 885–885. 2 indexed citations

Fani, Melpomeni & Guillaume Nicolas. (2023). ⁶¹Cu-Labeled Radiotracers: Alternative or Choice?. Journal of Nuclear Medicine. 64(12). 1855–1857. 11 indexed citations

10.

Ležaić, Luka, Clemens Decristoforo, Petra Kolenc Peitl, et al.. (2023). Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging. 50(13). 4110–4111. 1 indexed citations

11.

Gaonkar, Raghuvir H., Rosalba Mansi, Elsa Sánchez‐García, et al.. (2023). Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications. Journal of Medicinal Chemistry. 66(13). 8484–8497. 5 indexed citations

12.

Wild, Damian, Kwadwo Antwi, Melpomeni Fani, & Emanuel Christ. (2021). Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?. Journal of Nuclear Medicine. 62(Supplement 2). 44S–50S. 15 indexed citations

13.

Christ, Emanuel, Kwadwo Antwi, Melpomeni Fani, & Damian Wild. (2020). Innovative imaging of insulinoma: the end of sampling? A review. Endocrine Related Cancer. 27(4). R79–R92. 47 indexed citations

14.

Antwi, Kwadwo, Guillaume Nicolas, Melpomeni Fani, et al.. (2019). 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. The Journal of Clinical Endocrinology & Metabolism. 104(12). 5843–5852. 36 indexed citations

15.

Mansi, Rosalba & Melpomeni Fani. (2019). Design and development of the theranostic pair ¹⁷⁷Lu‐OPS201/⁶⁸Ga‐OPS202 for targeting somatostatin receptor expressing tumors. Journal of Labelled Compounds and Radiopharmaceuticals. 62(10). 635–645. 20 indexed citations

16.

Antwi, Kwadwo, Melpomeni Fani, Tobias Heye, et al.. (2018). Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. European Journal of Nuclear Medicine and Molecular Imaging. 45(13). 2318–2327. 97 indexed citations

17.

Christ, Emanuel, Damian Wild, Kwadwo Antwi, et al.. (2015). Preoperative localization of adult nesidioblastosis using 68Ga-DOTA-exendin-4-PET/CT. Endocrine. 50(3). 821–823. 35 indexed citations

18.

Wild, Damian, Melpomeni Fani, Richard Fischer, et al.. (2014). Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. Journal of Nuclear Medicine. 55(8). 1248–1252. 196 indexed citations

19.

Wang, Xuejuan, Melpomeni Fani, Stefan Schulz, et al.. (2012). Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 39(12). 1876–1885. 34 indexed citations

20.

Cescato, Renzo, et al.. (2011). Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. Bern Open Repository and Information System (University of Bern). 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact